FDA Approves Needle-Free Injector for Afluria Flu Vaccine
- By BSTQ Staff
The U.S. Food and Drug Administration (FDA) has approved PharmaJet Inc.’s Stratis 0.5mL Needle-Free Jet Injector for delivery of bioCSL Inc.’s AFLURIA influenza vaccine for individuals ages 18 to 64 years. This is the first needle-free delivery system approved by FDA for the administration of an inactivated influenza vaccine. In addition to AFLURIA, the injector is intended to deliver various medications and vaccines either intramuscularly or subcutaneously.
The PharmaJet injector delivers the vaccine by means of a narrow, precise fluid stream that penetrates the skin in about one-tenth of a second. No external power sources are required, and each needle-free syringe is sterile, auto disabling and cannot be reused. According to Pharmajet’s website, needle-free technology significantly reduces patient fear and anxiety associated with getting a needle injection. There is an audible click when the vaccine is delivered, and many report a preference for this technology. In a recent study, 89 percent of people receiving a needle-free injection indicated that they would choose the PharmaJet device for their next injection.
Needle-free technology eliminates needle-stick injuries to healthcare workers, greatly reduces the need for sharps disposal, and eliminates the possibility of cross-contamination. “The PharmaJet injection technology is an especially important innovation for the millions of individuals who suffer from fear of needles and who consequently forego their annual flu vaccine,” says Ron Lowy, PharmaJet CEO and co-chairman. “We believe this is a significant step forward in the effort to improve public health through broader immunization coverage, as well as improved safety of caregivers.”
To view the video demonstrating how the injectors works, go to www.pharmajet.com.
